Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis

Stefania Boccia, Gualtiero Ricciardi, L Manzoli, Me Flacco, E D’Andrea, N Panic, C Marzuillo, R Siliquini, P Villari, Jp Ioannidis

Research output: Contribution to journalConference article


Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.
Original languageEnglish
Pages (from-to)74-74
Number of pages1
JournalEuropean Journal of Public Health
Publication statusPublished - 2015
Event8th European Public Health Conference - Milano
Duration: 14 Oct 201517 Oct 2015


  • cardiovascular diseases
  • meta-analysis

Fingerprint Dive into the research topics of 'Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis'. Together they form a unique fingerprint.

Cite this